LigaChem Biosciences Inc. (KOSDAQ: 141080)

Market Cap	4.12T
Revenue (ttm)	76.22B
Net Income (ttm)	-33.95B
Shares Out	36.43M
EPS (ttm)	-1,079.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	946,420
Open	121,700
Previous Close	120,700
Day's Range	117,600 - 125,900
52-Week Range	40,500 - 143,600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About LigaChem Biosciences

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was for...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 157
• Stock Exchange: KOSDAQ
• Ticker Symbol: 141080

Financial Performance

In 2023, LigaChem Biosciences's revenue was 34.15 billion, an increase of 2.20% compared to the previous year's 33.41 billion. Losses were -73.70 billion, 63.5% more than in 2022.